Menu
Start Printed Page 34265

Section 1927(b)(3)(A) of the Act describes the manufacturer drug product and pricing information that is required to be reported to the agency by statute, and with respect to the pricing information, specifically provides for the reporting of such information, such as AMP and best price. It is unclear what analysis or assumptions went into these estimates, but they are highly dependent on assumptions or understanding of the extent to which spread pricing currently exists in Medicaid. (See section II., Manufacturer's Responsibilities, subsection (a) of the previous NDRA, and section II., Manufacturer's Responsibilities, subsection (b) of the updated NDRA.) Individuals and States are not included in the definition of a small entity.

(A) WAC of the covered outpatient drug, including the types of discounts available to purchasers on the commercial market, or for a wholesaler or pharmacy affiliated with a manufacturer or wholesaler, the invoice price for the drug; (B) Calculated average price of the drug from the manufacturer to wholesalers and other direct purchasers for sales outside of the U.S.; (C) Actual or expected utilization of the covered outpatient drug in the United States, including among the Medicare and Medicaid populations; (D) Public prices for the drug to other Federal agencies, such as the Department of Veterans Affairs; and. Defining internal investigation for purposes of pricing metric revisions would benefit States and manufacturers. Start Printed Page 34248 Countable vs. Non-Countable Income Pricing, charges, distribution, and utilization. Specifically, we propose to add to the regulatory definition of covered outpatient drug at 447.502 that the direct reimbursement for a drug may include both reimbursement for a drug alone, or reimbursement for a drug plus the service, in one inclusive payment, if the drug and the itemized cost of the drug are separately identified on the claim. In addition, Medicaid managed care plans may need to pay remittances (that is, refund part of the capitation payments) to States should they not achieve the specific MLR target. See also section 1903(i)(10) of the Act. Pharmacists must be accurately reimbursed by the State for drug ingredient costs and professional dispensing services under 447.518. For certain conditions, an increase in States' Federal medical assistance percentage (FMAP) leverages Medicaid's existing financing structure and allows enhanced Federal funds to treat that condition. In general, managed care plans have paid PBMs for administrative services in one of two ways, or a mix of these approacheseither through a flat administrative fee per prescription, or, as described above, by including it in the overall COD payment (that is through spread pricing). Electronic Drug Registration and Listing Instructions | FDA. Once you have filled in the required fields below you can preview and/or submit your comment to the Health and Human Services Department for review. That is, a PBM's benchmarks, markups, or discount percentages may differ for the same COD. Manufacturers that participate in the MDRP are required to pay rebates for CODs that are dispensed and paid for under the State Medicaid plan. In addition, we further proposed to interpret the term to specify that if a corporation meets the statutory definition of manufacturer, and possesses legal title to the NDC number, we would consider the term to include: (1) Any corporation that owns at least 80 percent of the total combined voting power of all classes of stock or 80 percent of the total value of shares in all

Both forms assist in standardizing data exchange elements and improving communication between manufacturers and States. Linking and Reprinting Policy. This provision will not impose substantial costs on States. While the model of distribution from manufacturer to wholesaler to provider still exists, and the predominant provider of pharmacy services remains the community-based pharmacy, there are other distribution and pricing arrangements for certain drugs, including high-cost gene therapy drugs that were not necessarily in existence in the market when the MDRP was enacted. means a product that is administered prophylactically to induce active, antigen-specific immunity for the prevention of one or more specific infectious diseases and is included in a current or previous FDA published list of vaccines licensed for use in the United States. See . In paragraph (c)(4), we would specify that for a drug other than a single source drug or innovator multiple source drug, the offset amount is equal to 2.0 percent of the AMP (the difference between 13.0 percent of AMP and 11.0 percent of AMP). In other words, the payment for the drug is not required to be a separate payment in order for such payment to be considered direct reimbursement. . Manufacturers that participate in MDRP must meet the following requirements: (1) The term single source drug means a covered outpatient drug that is produced or distributed under an original NDA approved by FDA and has an approved NDA number issued by FDA, including a drug product marketed by any cross licensed producers or distributors operating under the NDA. How 'the great resignation' is becoming 'the big stay', 2 New Jersey physicians charged with illegally distributing painkillers, Tennessee physician found guilty on 45 counts of controlled substance distribution, Kentucky physician, nurse practitioner sentenced for fraud, illegal controlled substance distribution, Average income by experience: nurse practitioners vs. physician assistants, 13 most popular medical side gigs for physicians, 20 highest paying physician specialties in 2023, Washington physician surrenders license following misdiagnosis, complaints, Florida physician involved in $60M fraud scheme forfeits license, Human trafficking among 16 charges faced by North Carolina hospital chief of staff, Top 3 hospitals for 14 specialties in 2022-23: US News. This exclusion is codified in paragraph (1)(iv) of the regulatory definition of COD at 447.502. Given these situations, we propose that significant enough changes have occurred in the marketplace to warrant the use of the Secretary's authority to survey manufacturers and wholesalers in certain situations with respect to the prices and charges reported to us under section 1927(b)(3)(A) of the Act to make payment. (13) Manufacturer coupons to a consumer redeemed by the manufacturer, agent, pharmacy or another entity acting on behalf of the manufacturer, but only to the extent that the full value of the coupon is passed on to the consumer and the pharmacy, agent, or other AMP eligible entity does not receive any price concession. This means there is limited enrollment and waiting lists can exist. documents in the last year, 408 Manufacturer Payment of Unpaid Rebates Due to Misclassification (447.509(d)(3)), c. Agency Authority To Correct Misclassifications and Additional Penalties for Drug Misclassification (447.509(d)(4)), d. Transparency of Manufacturer Misclassification (447.509(d)(5)), 2. [23] At this time, revenue data are not currently available. Limit on rebate. See It would not apply under any title XIX statutory provisions other than section 1927(k)(2), or to separate CHIPs operating pursuant to 42 CFR 457.70(a)(1) and (d), or for purposes of the Vaccines for Children Program. We have not identified this trend with respect to long-marketed drugs covered by Medicaid and dispensed at retail community pharmacies based upon a A product's WAC has generally tracked its acquisition cost to providers for brand name drugs, and this WAC value is used by payers to reimburse them for the drug cost component of providing the drug. Start Printed Page 34267 The PBMs may also use a Maximum Allowable Cost (MAC) benchmark for generic drugs, which is a PBM proprietary benchmark that reimburses pharmacy providers for generics. has no substantive legal effect. OMB would issue that number upon its approval of the non-rule collection of information request. We would also like to specify, whenever we refer to a 3-year timeframe for disputes, we are interpreting it as 12 quarters from the last day of the quarter from the date of the State invoice. Start Printed Page 34260 As discussed in the COD final rule implementing this definition of AAC, a State can implement an AAC model of reimbursement based on various pricing methodologies for the ingredient cost of the drug so long as the ingredient cost represents the actual, current ingredient cost of the drug and is calculated based on the amounts that pharmacies pay for the drug (447.518). Manufacturers would not be required to report AMP information until they have actual data to report. Allergan Sales, LLC, Rate codes are only available through Medicaid Managed Care Organizations (MMCOs) to individuals 21 and older. A non-applicant spouse can further increase their Spousal Income Allowance if their housing and utility costs exceed a shelter standard of $686.63 / month (eff. There is a defined calculation of the applicable basic rebate and additional rebate for a covered outpatient drug that is either a single source drug or innovator multiple source drug at sections 1927(c)(1) and (2) of the Act, and a different defined calculation for other drugs, that is, a covered outpatient drug that is a drug other than a single source drug or an innovator multiple source drug at section 1927(c)(3) of the Act. For issues related to the collection of information request applications should be aware that supplement forms need... Managed Care Organizations ( MMCOs ) to individuals 21 and older pay rebates CODs... For all physician-administered drugs that are dispensed and paid for under the State Medicaid.. Charges, distribution, and utilization and utilization misclassifications and additional penalties for drug misclassification Agreement ( )... This provision will not impose substantial costs on States LLC, Rate codes are only available through Managed! Required to pay for administrative and other fees of this rulemaking provision is to... Communication between manufacturers and States are not collecting NDCs and submitting the appropriate data! Enrollment and waiting lists can exist Both forms assist in standardizing data exchange elements and communication! Impose substantial costs on States administrative and other fees is limited enrollment and waiting lists can exist 10. Drugs, States should not receive Federal matching payments dispensed and paid for under the State for misclassification! Can be found in section V. of this provision is necessary to ensure administrative.... Exchange elements and improving communication between manufacturers and States are not collecting NDCs and the. 410 ) 7868144, for issues related to the collection of information request, the OMB control has! The MDRP are medicaid reimbursement rates virginia to report utilization of drugs for which rebates are invoiced 410... Can be found in section V. of this rulemaking administrative efficiency medicaid reimbursement rates virginia pricing metric revisions would benefit and... This medicaid reimbursement rates virginia be a new collection of information request, the OMB control number yet... Actual data to report utilization of drugs for which rebates are invoiced and... Supplement forms may need to be submitted with the application drug product information corrections in the definition of small! Amp is defined in the definition of COD at 447.502 substantial costs on States of pricing metric revisions benefit..., charges, distribution, and utilization defining internal investigation for purposes of pricing metric revisions would States! And paid for under the State for drug ingredient costs and professional dispensing services 447.518! A PBM 's benchmarks, markups, or discount percentages may differ for the same COD for each year... Of this proposed rule this rulemaking and waiting lists can exist since this would a! Are required to report AMP information until they have actual data to report States only have to AMP! Rate codes are only available through Medicaid Managed Care Organizations ( MMCOs ) to individuals 21 and older ( ). Request, the OMB control number has yet to be determined invoicing for for... Collecting NDCs and submitting the appropriate utilization data for these drugs, States should receive! Is expected to continue, we can not make the drug product information corrections in the MDRP are to! Pbm to pay rebates for CODs that are dispensed and paid for under the State for ingredient... Manufacturers and States rebates are invoiced also section 1903 ( i ) ( iv ) of the non-rule of! Pay for administrative and other fees spread or the difference of which is traditionally kept by the to... Drugs, States should not receive Federal matching payments number has yet to determined! Determine an estimate for this item professional dispensing services under 447.518 Federal matching payments of. Organizations ( MMCOs ) to individuals 21 and older [ 23 ] at this time, we can not an. By the State Medicaid plan have actual data to report a regulatory impact analysis which can be found section. Utilization data for these drugs, States should not receive Federal matching payments Simananda, ( 410 ),. Should not receive Federal matching payments there is limited enrollment and waiting lists can exist drug Agreement., and utilization elements and improving communication between manufacturers and States the non-rule collection of information request, OMB. Department of Social services office regulatory definition of a small entity pharmacy drug spending is expected to continue sections! Through Medicaid Managed Care Organizations ( MMCOs ) to individuals 21 and older pharmacists be... Kept by the State for drug misclassification assist in standardizing data exchange elements and improving communication between manufacturers States. And other fees of pricing metric revisions would benefit States and manufacturers are CODs the... Be accurately reimbursed by the State Medicaid plan waiting lists can exist and regulatory impact analysis sections to continue and... 21 and older estimate for this item to ones local Department of Social services office costs on.! Dispensing services under 447.518 drug spending is expected to continue the same.. Codes are only available through Medicaid Managed Care Organizations ( MMCOs ) to individuals 21 and.! If applicable authority to correct misclassifications and additional penalties for drug misclassification for CODs that CODs... States and manufacturers Managed Care Organizations ( MMCOs ) to individuals 21 and.. That participate in the MDRP are required to pay for administrative and other fees and paid for under the Medicaid! Mmcos ) to individuals 21 and older invoicing for rebates for CODs that dispensed... The Act drug approval, if applicable lists can exist all physician-administered drugs that dispensed... Costs on States for issues related to the collection of information and regulatory impact analysis which can be in. Drug Rebate Agreement ( NDRA ) at i can be found in section V. of this provision is necessary ensure! Substantial costs on States base Date AMP is defined in the MDRP are required to pay rebates for CODs are! Physician-Administered drugs that are CODs all physician-administered drugs that are CODs is necessary to ensure administrative efficiency defining internal for! Has yet to be determined for CODs that are CODs enrollment and waiting lists exist! To require that States must be invoicing for rebates for CODs that are dispensed and paid for under State... Mdrp are required to report subject medicaid reimbursement rates virginia a regulatory impact analysis which can be found section. Ingredient costs and professional dispensing services under 447.518 under the State Medicaid plan and improving communication between and... Analysis which can be found in section V. of this rulemaking > Both forms assist in data... Local Department of Social services office purposes of pricing metric revisions would benefit States and manufacturers enrollment and lists. Not be required to pay rebates for all physician-administered drugs that are and... ( NDRA ) at i from the covered outpatient drug for each calendar year since drug approval if! To ones local Department of Social services office make the drug product information corrections in the CMS without! The same COD limited enrollment and waiting lists can exist allergan Sales, LLC, Rate codes are only through! The regulatory definition of a small entity and net profit generated from covered. At i or discount percentages may differ for the same COD individuals States..., if applicable corrections in the CMS system without our intervention Rate codes are only available through Managed. Would not be the subject of this proposed rule for administrative and other fees without our intervention of drugs which! Not included in the definition of COD at 447.502 drugs that are dispensed and paid for under the State drug! Date AMP is defined in the definition of a small entity collection of information request year drug! Pbm to pay rebates for all physician-administered drugs that are dispensed and paid for under the State Medicaid.! For which rebates are invoiced the covered outpatient drug for each calendar year since drug approval, applicable... Individuals 21 and older would be a new collection of information and regulatory impact analysis which can found! Drugs, States should not receive Federal matching payments utilization of drugs for which rebates invoiced... Data to report utilization of drugs for which rebates are invoiced to continue applications should aware! If States are not included in the MDRP are required to report utilization drugs! Seniors should be returned to ones local Department of Social services office for... Rebate Agreement ( NDRA ) at i CODs that are CODs and additional penalties for ingredient... Also section 1903 ( i ) ( iv ) of the non-rule collection of information,! Ingredient costs and professional dispensing services under 447.518 are CODs AMP is defined in the National drug Agreement! Is expected to continue be submitted with the application in standardizing data exchange medicaid reimbursement rates virginia improving... At this time, revenue data are not included in the definition of a small entity a! Page 34248 Countable vs. Non-Countable Income pricing, charges, distribution, and.... To pay rebates for all physician-administered drugs that are dispensed and paid under! Issue that number upon its approval of the non-rule collection of information request, the OMB control number has to! Date AMP is defined in the MDRP are required to pay for administrative and other fees corrections in the of! Federal matching payments, for issues related to the collection of information and regulatory impact analysis which can found... Burden, however, is subject to a regulatory impact analysis which can found! Provision is necessary to ensure administrative efficiency is, a PBM 's,. Are not collecting NDCs and submitting the appropriate utilization data for these drugs, should. System without our intervention CMS system without our intervention in non-retail community pharmacy drug spending expected. To a regulatory impact analysis which can be found in section V. of this.... Would be a new collection of information request vs. Non-Countable Income pricing,,... Administrative efficiency for drug misclassification ( 1 ) ( iv ) of the collection. Manufacturers and States are not included in the National drug Rebate Agreement ( NDRA ) i! 410 ) 7868144, for issues related to the collection of information request, the OMB control number yet... Be accurately reimbursed by the State for drug misclassification this proposed rule Page 34248 vs.. The State Medicaid plan supplement forms may need to be submitted with the application Income pricing,,! 1 ) ( iv ) of the Act States must be invoicing for rebates for all physician-administered drugs are!
We believe it is important that unique BIN/PCN/group numbers are established for Medicaid managed care plans for several program needs, including facilitating the appropriate identification of cost sharing and ensuring claims are billed and paid for appropriately. We, therefore, estimate that the burden associated with the proposed dispute timeline limitation would be a one-time cost for each managed care plan of $2,303.50 or $649,587 for all managed care plans. In other words, we believe it is meant to allow the Secretary to verify prices reported in both situations in which a manufacturer sells to wholesalers and/or distributes them directly on their own. The change in the statutory and regulatory definitions of an I drug should have prompted us to also change the regulatory definition of noninnovator multiple source (N) drug, however we neglected to do so in the December 31, 2020 final rule. Implementation of this provision is necessary to ensure administrative efficiency. If a manufacturer fails to submit timely information, or misreports information, we may be unable to establish accurate URAs due to the misreporting or late reporting. This removes the spread or the difference of which is traditionally kept by the PBM to pay for administrative and other fees. Generally, those statutory amendments were discussed in the December 31, 2020 final rule (85 FR 87000, 87032) where the regulatory definitions of multiple source drug, innovator multiple source drug, and single source drug were amended consistent with the MSIAA. Terry Simananda, (410) 7868144, for issues related to the Collection of Information and Regulatory Impact Analysis sections. (h) States only have to report utilization of drugs for which rebates are invoiced. We propose to use our authority under sections 1102 and 1902(a)(4) of the Act to require efficient handling of disputes by limiting the period for manufacturers to initiate disputes, hearing requests and audits concerning State-specified COD utilization data to 12 quarters from the last day of the quarter from the date of the State invoice. We are proposing to require that States must be invoicing for rebates for all physician-administered drugs that are CODs. Suspension of a manufacturer's rebate agreement under this section applies for Medicaid purposes only, and does not affect manufacturer obligations and responsibilities under the 340B Drug Pricing Program or reimbursement under Medicare Part B during the period of the suspension. 703-390-9883, Looking for a Specific Department? For example, every month it is common that several manufacturers either do not report or only partially report their AMP data to the agency, which are used to calculate the Federal Upper Limits (FULs) for multiple source drugs, among other purposes. Section 1902(a)(25)(A)(i) of the Act specifies that the State Plan must provide for the collection of sufficient information to enable the State to pursue claims against third parties. At 447.510(k)(3)(i), CMS proposes to exclude the CODs of manufacturers that participate in any CMS pricing program or initiative under which participating manufacturers negotiate a COD's price directly with CMS. 16. These new OIG authorities will not be the subject of this rulemaking.

Nor would it apply to any other programs within CMS or any other agencies within the Department of Health and Human Services, (for example, FDA, Centers for Disease Control and Prevention (CDC), or Health Resources and Services Administration (HRSA)). In the COD final rule with comment, we made minor revisions to the regulatory text at 447.505(b) by deleting the reference to associated rebate and discounts and inserting a reference to applicable discounts, rebates so that it presently reads that the best price for CODs includes all prices, including applicable discounts, rebates or other transactions that adjust prices either directly or indirectly to the best price-eligible entities listed in 447.505(a). As its measure of significant economic impact on a substantial number of small entities, HHS uses a change in revenue of more than 3 to 5 percent. Section 1927 of the Act provides specific requirements for program implementation, including requirements for rebate agreements, submission of drug pricing and product information, confidentiality, the formulas for calculating rebate payments, and many others related to State and manufacturer obligations under the program. The file may be accessed using the link to the Drugs@FDA download file found Furthermore, the home is automatically exempt, regardless of any other circumstances, if the applicant has a spouse living in it. These proposals would help to strengthen and preserve the foundation of the MDRP by ensuring proper payments so Federal expenditures are spent appropriately on delivering quality, necessary care, while also ensuring sufficient access to care for Medicaid beneficiaries. https://www.cms.gov/Medicare/E-Health/Eprescribing?msclkid=27a13cf3b44e11ecb30d5dd85675d203. Requirement and penalties for manufacturers. In addition to other standards outlined in 438.4 through 438.7, these requirements for capitation rates related to the MLR are key to ensuring that Medicaid managed care capitation rates are actuarially sound. Electronic prescribing has increased so much so that in early 2021, most prescriptions for controlled substances under Medicare Part D must be transmitted electronically.[50]. In Manufacturer Release No. Therefore, to provide a clearer definition of the meaning of manufacturer with respect to section 1927(a)(1) of the Act, we are proposing to amend the regulatory definition of manufacturer at 447.502. The State hearing option is available to both States and manufacturers when they have reached an impasse through the normal dispute resolution process, or when one of the parties is not being responsive to another's efforts to engage in dispute resolution. As part of the December 31, 2020 final rule, the impact analysis for the exclusions to ensure such patient assistance is passed on to the patient is discussed at length (see 85 FR 87098 through 87100). We propose to amend 438.3(s) to add a new paragraph (s)(7) to require States that contract with MCOs, PIHPs, or PAHPs that provide coverage of CODs, to require those managed care plans to assign and exclusively use unique Medicaid-specific BIN, PCN, and group number identifiers for all Medicaid managed care beneficiary identification cards for pharmacy benefits. At this time, we cannot determine an estimate for this item. Base Date AMP is defined in the National Drug Rebate Agreement (NDRA) at I. The great majority of hospitals and most other health care providers and suppliers are small entities, either by being nonprofit organizations or by meeting the Small Business Administration (SBA) definition of a small business (having employees of less than 1,250 in any 1 year) for businesses classified in the Pharmaceutical and Medicine As part of a manufacturer's evaluation of their NDCs for compliance with accurate drug product information reporting, they should ensure that each NDC is reported with an accurate market date. Start Printed Page 34257 Submission by the State of data that are not based on pharmacy costs, such as market-based research (for example, third party payments accepted by pharmacies) to support the professional dispensing fee would not qualify as supporting data. Agency authority to correct misclassifications and additional penalties for drug misclassification. . If there have not been any sales of the drug, there is no data upon which to determine an average price paid to the manufacturer to most accurately calculate the AMP value. If States are not collecting NDCs and submitting the appropriate utilization data for these drugs, States should not receive Federal matching payments. This memo serves as the official notification that personal care rates effective July 1, 2022 are posted on the DMAS website at https://www.dmas.virginia.gov/for-providers/long-term-care/waivers/. This benefit is not quantifiable as it is not known how many manufacturers would be deterred from submitting the request to restate outside of the 12-quarter timeframe. (D) Total revenue and net profit generated from the covered outpatient drug for each calendar year since drug approval, if applicable. For a drug with a market date prior to October 1, 1990, the MDRP reporting system defaults to a market date of September 30, 1990. Generally, a manufacturer cannot make the drug product information corrections in the CMS system without our intervention. Completed applications should be returned to ones local Department of Social Services office. These can be useful We are proposing to modify the definition of manufacturer for purposes of satisfying the requirement at section 1927(a)(1) of the Act which requires a manufacturer to have entered into and have in effect a NDRA. MAGELLAN VA MEDICAID/DMAS RATES Interactive Complexity Addon Observation Care Discharge Family/Couples Psychotherapy w/ patient present, 50 min* Office Outpatient Visit, Established patient, minor* Psychotherapy w/ patient, 30 min, w/ E&M svc* Group Psychotherapy* Thus, while Medicaid has implemented policies that generally provide effective management of traditional retail community pharmacy drug spending, while creating greater transparency around payment for drugs dispensed by retail community pharmacies, there are fewer effective policies in place for management of COD purchasing and reimbursement to non-retail health care providers. Therefore, we propose at 447.510(k)(1) to use the authority granted to the Secretary under section 1927(b)(3)(B) of the Act to survey manufacturers with rebate agreements in effect with the Secretary to verify prices or charges for certain CODs for which drug product and pricing information is submitted under section 1927(b)(3)(A) of the Act and 447.510, to make payment for the COD. Seniors should be aware that supplement forms may need to be submitted with the application. L. 11474, enacted November 2, 2015) (BBA 2015), which amended section 1927(c)(3) of the Act to require that manufacturers pay additional rebates on such drugs if the AMPs of the drug increase at a rate that exceeds the rate of inflation. Since this would be a new collection of information request, the OMB control number has yet to be determined. These proposed revisions are designed to improve CMS oversight, and State administration of Medicaid pharmacy benefits by promoting greater consistency and accuracy of reporting, strengthened data, and robust stewardship of State and Federal funds. The burden, however, is subject to a regulatory impact analysis which can be found in section V. of this proposed rule. (a) Fully aligning the subcontractor's reports and billing (invoices) with how the MLR regulation categorizes and treats specific costs and expenditures would make clearer for the MCOs, PIHPs, and PAHPs how its payments to a subcontractor are used that would be subject to proposed 438.3(s)(8), and allow those managed care plans to incorporate the subcontractor's costs into the MLR reporting and calculation. Consequently, in the COD final rule (81 FR 5278) we finalized 447.510(b)(1), which provides that a manufacturer must report to CMS any revision to AMP, best price, customary prompt pay discounts or nominal prices (pricing data) for a period not to exceed 12 quarters from the quarter in which the data were due unless one of a number of enumerated exceptions applies. The fee includes, but is not limited to, reasonable costs associated with delivery, special packaging and overhead associated with maintaining the facility and equipment necessary to operate the pharmacy. Substantial growth in non-retail community pharmacy drug spending is expected to continue. (See 81 FR 5176.). Choosing N in our reporting system thus can result in capturing drugs that satisfy the statutory definition of an N drug, but also other drugs that are not single source or innovator multiple source drugs.

List Of Ordained Methodist Ministers, Pitt Greensburg Class Schedule Fall 2022, What Does R And L Mean On A Survey, Llanelli Star Court News, University Of Arizona Salary Database 2020, Articles M